Benefits of α‑lipoic acid in high‑risk pregnancies (Review)

  • Authors:
    • Aida Petca
    • Mihaela Bot
    • Nicoleta Maru
    • Ioana Gabriela Calo
    • Andreea Borislavschi
    • Mihai Cristian Dumitrascu
    • Razvan-Cosmin Petca
    • Florica Sandru
    • Mona Elena Zvanca
  • View Affiliations

  • Published online on: August 31, 2021     https://doi.org/10.3892/etm.2021.10666
  • Article Number: 1232
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

α‑Lipoic acid (ALA) is a natural molecule that is inconsistently synthesized by the human body and must be provided from exogenous sources, such as food and dietary supplements. Once absorbed, the oxidized form of ALA is transformed into its reduced form, dihydrolipoic acid (DHLA). ALA/DHLA exert direct and indirect antioxidant, anti‑inflammatory and fine immunomodulatory effects. ALA/DHLA reduce the levels of pro‑inflammatory cytokines (IL‑1β, IL‑6, IL‑8 and IL‑17), while increasing the secretion of anti‑inflammatory cytokines (IL‑10). They also inhibit cyclooxygenase 2, thereby decreasing the secretion of prostaglandin E2 and nitrogen oxide, and reducing the risk of miscarriage in the first trimester of pregnancy. In patients at risk of abortion, administration of ALA from the first trimester has shown efficacy by accelerating subchorionic hematoma resorption, with a significant decrease in the accompanying abdominal pain. ALA has been proven to be efficient in maintaining the length of the cervix and keeping it closed following one episode of premature labor. Preeclampsia is a dysfunction caused by abnormal placentation and an excessive maternal inflammatory response, leading to extreme hypoxia in the placental bed and exaggerated oxidative stress, with release of oxygen free radicals. Oxidative stress plays a key role in the development of preeclampsia and intrauterine growth restriction. The hypothesis of antioxidant supplementation may play an essential part in disease prevention and fetal neuroprotection.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 22 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Petca A, Bot M, Maru N, Calo IG, Borislavschi A, Dumitrascu MC, Petca R, Sandru F and Zvanca ME: Benefits of α‑lipoic acid in high‑risk pregnancies (Review). Exp Ther Med 22: 1232, 2021
APA
Petca, A., Bot, M., Maru, N., Calo, I.G., Borislavschi, A., Dumitrascu, M.C. ... Zvanca, M.E. (2021). Benefits of α‑lipoic acid in high‑risk pregnancies (Review). Experimental and Therapeutic Medicine, 22, 1232. https://doi.org/10.3892/etm.2021.10666
MLA
Petca, A., Bot, M., Maru, N., Calo, I. G., Borislavschi, A., Dumitrascu, M. C., Petca, R., Sandru, F., Zvanca, M. E."Benefits of α‑lipoic acid in high‑risk pregnancies (Review)". Experimental and Therapeutic Medicine 22.5 (2021): 1232.
Chicago
Petca, A., Bot, M., Maru, N., Calo, I. G., Borislavschi, A., Dumitrascu, M. C., Petca, R., Sandru, F., Zvanca, M. E."Benefits of α‑lipoic acid in high‑risk pregnancies (Review)". Experimental and Therapeutic Medicine 22, no. 5 (2021): 1232. https://doi.org/10.3892/etm.2021.10666